Health & Science · October 28, 2026
FDA scientists opposed Trump administration’s move to ease peptide access
The Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., released a new policy on Wednesday easing access to six injectable peptides. These substances, which include BPC-157, are often promoted in the wellness industry for muscle building, injury recovery, and energy enhancement. The policy directs the FDA to refrain from taking enforcement action against specialty pharmacies selling these products. Reporting indicates that the move faced significant internal opposition from FDA scientific staff, who argued the change could undermine the agency's standards for ensuring health products on the U.S. market are proven safe and effective.
Read the original coverage
- The GuardianMainstream
FDA scientists opposed Trump administration’s move to ease peptide access
Read at The Guardian ↗ - Raw StoryIndependent
Scientists rebel over RFK Jr.
Read at Raw Story ↗ - MedPage TodayTrade
RFK Jr. Eases Access to Unproven Peptides Despite Opposition From FDA Scientists
Read at MedPage Today ↗
Reported by multiple outlets
- HHS posted a new policy online on Wednesday easing access to specific injectable peptides.
- The policy directs the FDA not to take action against specialty pharmacies selling these peptides.
- Six people familiar with the development of the policy reported that FDA scientific staff opposed the move.
- The peptides in question are marketed for wellness purposes such as muscle growth and injury healing.
- FDA staffers had limited input in drafting the new policy.
Reported by only some outlets
- One of the specific peptides included in the policy is BPC-157.
- Robert F. Kennedy Jr. has previously referred to himself as a 'big fan' of peptides.
What the evidence actually shows
There is no specific study cited; the articles discuss a Department of Health and Human Services policy memorandum that prevents the FDA from enforcing restrictions on six specific wellness peptides.
What experts dispute
- FDA scientific staff dispute the safety and efficacy of these peptides, warning they are 'unproven'.
FreeDaily Brief newsletter
Get the 5-minute Daily Brief, with the topics you pick.
The Daily Brief is free
About these outlets
CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.